Compare Citius Pharmaceuticals Inc (CTXR) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Huntington Bancshares Incorporated — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Huntington Bancshares Incorporated trades at $15.31 (market cap $31.04B). The key difference: Huntington Bancshares Incorporated is far larger — about 2279× Citius Pharmaceuticals Inc's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Huntington Bancshares Incorporated for 52 Days on average.
| CTXR | HBAN | |
|---|---|---|
Market Cap | $13.62M | $31.04B |
Volume | 132,438 | 23,864,172 |
Sector | Health | Financials |
52-Week High | $1.82 | $19.27 |
52-Week Low | $0.48 | $15.02 |
Typical Hold Time | 17 Days | 52 Days |
Enterprise Value | $3.79M | $49.57B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Huntington Bancshares (HBAN) trades at $15.32, up 0.99% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $8.13B and net income of $2.21B, with a P/E of 11.82 and ROE of 9.23%. Recent news highlights an increased prime rate to 7.00% and a revised 2027 earnings outlook due to margin pressures.
Outlook is cautious; analyst consensus is a Buy with a $19.60 price target, but near-term headwinds from higher interest rates and deposit costs pose risks. The stock offers value based on valuation metrics, yet investors should weigh margin pressures against shareholder return initiatives like the $550M buyback plan for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
